RARE Ultragenyx Pharmaceutical Inc

Price (delayed)

$51.71

Market cap

$4.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.25

Enterprise value

$4.09B

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of ...

Highlights
The revenue rose by 20% year-on-year and by 6% since the previous quarter
RARE's EPS is up by 18% year-on-year and by 8% since the previous quarter
Ultragenyx Pharmaceutical's debt has increased by 37% YoY but it has decreased by 7% from the previous quarter
The quick ratio has decreased by 23% YoY but it has increased by 13% QoQ
The equity has declined by 22% year-on-year
The gross margin has decreased by 2.8% YoY

Key stats

What are the main financial stats of RARE
Market
Shares outstanding
82.34M
Market cap
$4.26B
Enterprise value
$4.09B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
15.42
Price to sales (P/S)
8.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.41
Earnings
Revenue
$434.25M
EBIT
-$608.46M
EBITDA
-$582.46M
Free cash flow
-$519.07M
Per share
EPS
-$8.25
Free cash flow per share
-$7.06
Book value per share
$3.35
Revenue per share
$5.9
TBVPS
$17.41
Balance sheet
Total assets
$1.49B
Total liabilities
$1.22B
Debt
$43.17M
Equity
$275.41M
Working capital
$451.75M
Liquidity
Debt to equity
0.16
Current ratio
2.61
Quick ratio
2.32
Net debt/EBITDA
0.29
Margins
EBITDA margin
-134.1%
Gross margin
89.6%
Net margin
-139.7%
Operating margin
-131.2%
Efficiency
Return on assets
-44.7%
Return on equity
-369.5%
Return on invested capital
-74.2%
Return on capital employed
-50.3%
Return on sales
-140.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RARE stock price

How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
-1.97%
1 week
5.79%
1 month
12.44%
1 year
16.23%
YTD
8.13%
QTD
8.13%

Financial performance

How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$434.25M
Gross profit
$389.04M
Operating income
-$569.55M
Net income
-$606.64M
Gross margin
89.6%
Net margin
-139.7%
Ultragenyx Pharmaceutical's net margin has increased by 28% YoY and by 10% from the previous quarter
The company's operating margin rose by 27% YoY and by 10% QoQ
The revenue rose by 20% year-on-year and by 6% since the previous quarter
The company's gross profit rose by 16% YoY and by 4.7% QoQ

Growth

What is Ultragenyx Pharmaceutical's growth rate over time

Valuation

What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
15.42
P/S
8.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.41
RARE's EPS is up by 18% year-on-year and by 8% since the previous quarter
RARE's price to book (P/B) is 53% less than its last 4 quarters average of 33.2 but 38% more than its 5-year quarterly average of 11.4
The equity has declined by 22% year-on-year
The P/S is 57% lower than the 5-year quarterly average of 21.0 but 19% higher than the last 4 quarters average of 7.5
The revenue rose by 20% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Ultragenyx Pharmaceutical business performance
The ROE has dropped by 200% year-on-year and by 7% since the previous quarter
RARE's return on sales is up by 27% year-on-year and by 9% since the previous quarter
The company's return on invested capital rose by 8% YoY
The return on assets has increased by 7% year-on-year and by 3.7% since the previous quarter

Dividends

What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RARE.

Financial health

How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 23% more than the total liabilities
The quick ratio has decreased by 23% YoY but it has increased by 13% QoQ
The current ratio is down by 23% YoY but it is up by 11% QoQ
Ultragenyx Pharmaceutical's debt is 84% less than its equity
Ultragenyx Pharmaceutical's debt to equity has plunged by 89% from the previous quarter but it has soared by 78% YoY
Ultragenyx Pharmaceutical's debt has increased by 37% YoY but it has decreased by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.